Plato Investment Management Ltd Has $2.30 Million Stock Position in IQVIA Holdings Inc. $IQV

Plato Investment Management Ltd cut its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 21.7% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 10,150 shares of the medical research company’s stock after selling 2,815 shares during the period. Plato Investment Management Ltd’s holdings in IQVIA were worth $2,299,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of IQV. Brighton Jones LLC raised its holdings in IQVIA by 244.4% in the 4th quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock valued at $703,000 after buying an additional 2,537 shares during the last quarter. Empowered Funds LLC increased its position in IQVIA by 102.1% in the 1st quarter. Empowered Funds LLC now owns 9,728 shares of the medical research company’s stock valued at $1,715,000 after acquiring an additional 4,915 shares during the period. Sivia Capital Partners LLC bought a new position in shares of IQVIA during the second quarter valued at $514,000. First Trust Advisors LP lifted its holdings in shares of IQVIA by 14.8% during the second quarter. First Trust Advisors LP now owns 92,015 shares of the medical research company’s stock worth $14,501,000 after purchasing an additional 11,845 shares during the period. Finally, NewEdge Advisors LLC grew its stake in shares of IQVIA by 5.4% in the second quarter. NewEdge Advisors LLC now owns 22,731 shares of the medical research company’s stock worth $3,582,000 after purchasing an additional 1,155 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on IQV. Jefferies Financial Group lowered their target price on IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a research report on Friday, February 6th. Barclays raised IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 price target for the company in a research note on Friday, March 6th. Weiss Ratings lowered IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday, May 4th. Wall Street Zen raised shares of IQVIA from a “hold” rating to a “buy” rating in a research report on Sunday, April 19th. Finally, Morgan Stanley set a $225.00 price target on shares of IQVIA in a research report on Thursday. Two research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, IQVIA currently has an average rating of “Buy” and an average target price of $225.69.

IQVIA Stock Down 0.1%

Shares of NYSE:IQV opened at $178.48 on Monday. IQVIA Holdings Inc. has a 1 year low of $134.65 and a 1 year high of $247.04. The company has a debt-to-equity ratio of 2.20, a current ratio of 0.75 and a quick ratio of 0.75. The business’s 50-day moving average is $170.14 and its 200-day moving average is $200.95. The company has a market capitalization of $29.79 billion, a price-to-earnings ratio of 22.12, a P/E/G ratio of 1.72 and a beta of 1.18.

IQVIA (NYSE:IQV) last released its earnings results on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, topping the consensus estimate of $2.83 by $0.07. The business had revenue of $4.15 billion during the quarter, compared to analysts’ expectations of $4.10 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The firm’s revenue was up 8.4% on a year-over-year basis. During the same quarter last year, the firm posted $2.70 earnings per share. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Equities research analysts predict that IQVIA Holdings Inc. will post 11.5 earnings per share for the current year.

IQVIA declared that its board has initiated a share buyback plan on Thursday, May 7th that authorizes the company to buyback $2.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to buy up to 6.8% of its stock through open market purchases. Stock buyback plans are often a sign that the company’s leadership believes its shares are undervalued.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.